1. Adelaide Research & Scholarship
  2. Schools and Disciplines
  3. School of Medicine
  4. Medicine
  5. Medicine publications
Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/89454
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBranford, S.-
dc.contributor.authorRoss, D.-
dc.contributor.authorYeung, D.-
dc.contributor.authorBraley, J.-
dc.contributor.authorHughes, T.-
dc.date.issued2014-
dc.identifier.citationBlood, 2014, vol.124, iss.21, pp.4561-4561-
dc.identifier.issn0006-4971-
dc.identifier.issn1528-0020-
dc.identifier.urihttp://hdl.handle.net/2440/89454-
dc.description.statementofresponsibilitySusan Branford, David M Ross, David T Yeung, Jodi Braley, and Timothy P. Hughes-
dc.language.isoen-
dc.publisherAmerican Society of Hematology-
dc.rights© 2014 by The American Society of Hematology-
dc.source.urihttp://www.bloodjournal.org/content/124/21/4561-
dc.titleAchieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint-
dc.typeConference item-
dc.contributor.conference56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)-
pubs.publication-statusPublished-
dc.identifier.orcidBranford, S. [0000-0002-1964-3626] [0000-0002-5095-7981]-
dc.identifier.orcidRoss, D. [0000-0001-7171-2935]-
dc.identifier.orcidYeung, D. [0000-0002-7558-9927]-
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]-
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.